Goldman Sachs’s Crinetics Pharmaceuticals CRNX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $41.3M | Buy |
1,104,998
+476,843
| +76% | +$17.7M | ﹤0.01% | 1978 |
|
|
2026
Q1 | $22.8M | Buy |
628,155
+61,028
| +11% | +$2.73M | ﹤0.01% | 2305 |
|
|
2025
Q4 | $26.4M | Sell |
567,127
-146,003
| -20% | -$6.5M | ﹤0.01% | 2107 |
|
|
2025
Q3 | $29.7M | Sell |
713,130
-187,757
| -21% | -$6M | ﹤0.01% | 1877 |
|
|
2025
Q2 | $25.9M | Buy |
900,887
+401,293
| +80% | +$12.4M | ﹤0.01% | 1894 |
|
|
2025
Q1 | $16.8M | Sell |
499,594
-221,675
| -31% | -$8.28M | ﹤0.01% | 2194 |
|
|
2024
Q4 | $36.9M | Sell |
721,269
-65,759
| -8% | -$3.68M | 0.01% | 1555 |
|
|
2024
Q3 | $40.2M | Buy |
787,028
+137,838
| +21% | +$7.11M | 0.01% | 1426 |
|
|
2024
Q2 | $29.1M | Sell |
649,190
-214,917
| -25% | -$9.92M | ﹤0.01% | 1561 |
|
|
2024
Q1 | $40.4M | Buy |
864,107
+213,934
| +33% | +$8.37M | 0.01% | 1299 |
|
|
2023
Q4 | $23.1M | Buy |
650,173
+97,575
| +18% | +$2.99M | ﹤0.01% | 1770 |
|
|
2023
Q3 | $16.4M | Sell |
552,598
-62,248
| -10% | -$1.28M | ﹤0.01% | 1974 |
|
|
2023
Q2 | $11.1M | Buy |
614,846
+94,648
| +18% | +$1.89M | ﹤0.01% | 2345 |
|
|
2023
Q1 | $8.35M | Buy |
520,198
+386,882
| +290% | +$7.16M | ﹤0.01% | 2580 |
|
|
2022
Q4 | $2.44M | Buy |
133,316
+10,648
| +9% | +$188K | ﹤0.01% | 3789 |
|
|
2022
Q3 | $2.41M | Buy |
122,668
+25,215
| +26% | +$514K | ﹤0.01% | 3819 |
|
|
2022
Q2 | $1.82M | Sell |
97,453
-13,150
| -12% | -$262K | ﹤0.01% | 4124 |
|
|
2022
Q1 | $2.43M | Buy |
110,603
+49,083
| +80% | +$993K | ﹤0.01% | 4078 |
|
|
2021
Q4 | $1.75M | Buy |
61,520
+6,095
| +11% | +$150K | ﹤0.01% | 4360 |
|
|
2021
Q3 | $1.17M | Sell |
55,425
-5,380
| -9% | -$113K | ﹤0.01% | 4620 |
|
|
2021
Q2 | $1.15M | Sell |
60,805
-61,547
| -50% | -$1.08M | ﹤0.01% | 4659 |
|
|
2021
Q1 | $1.87M | Sell |
122,352
-5,830
| -5% | -$90.4K | ﹤0.01% | 4055 |
|
|
2020
Q4 | $1.81M | Buy |
128,182
+26,790
| +26% | +$373K | ﹤0.01% | 3803 |
|
|
2020
Q3 | $1.59M | Buy |
101,392
+87,349
| +622% | +$1.34M | ﹤0.01% | 3735 |
|
|
2020
Q2 | $246K | Buy |
+14,043
| New | +$239K | ﹤0.01% | 4713 |
|
|
2019
Q4 | – | Sell |
-72,640
| Closed | -$1.09M | – | 5236 |
|
|
2019
Q3 | $1.09M | Sell |
72,640
-108,350
| -60% | -$2.11M | ﹤0.01% | 3971 |
|
|
2019
Q2 | $4.53M | Buy |
180,990
+166,599
| +1,158% | +$4.13M | ﹤0.01% | 2921 |
|
|
2019
Q1 | $328K | Buy |
14,391
+3,417
| +31% | +$84K | ﹤0.01% | 4589 |
|
|
2018
Q4 | $329K | Buy |
+10,974
| New | +$309K | ﹤0.01% | 4589 |
|
Other funds holding CRNX
FCM
DCM
JT
Goldman Sachs's CRNX Position: Q2 2026 in Review
Goldman Sachs increased its Crinetics Pharmaceuticals (CRNX) stake by 76% in Q2 2026, buying an estimated $17.7M and bringing the position to 1,104,998 shares worth $41.3M. The position accounts for ﹤0.01% of the portfolio, ranked #1978.
Goldman Sachs first reported a position in CRNX in Q4 2018 and has held it in 29 quarters since. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.
- Goldman Sachs held 1,104,998 shares of Crinetics Pharmaceuticals worth $41.3M as of Q2 2026.
- Goldman Sachs bought 476,843 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $17.7M.
- Crinetics Pharmaceuticals made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #1978 holding.
- Goldman Sachs first reported a position in Crinetics Pharmaceuticals in Q4 2018 and has held it in 29 quarters since.
- 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.
Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.